Vis enkel innførsel

dc.contributor.authorAnisdahl, Karoline
dc.contributor.authorLirhus, Sandre Svatun
dc.contributor.authorMedhus, Asle Wilhelm
dc.contributor.authorMoum, Bjørn Allan
dc.contributor.authorMelberg, Hans Olav
dc.contributor.authorHøivik, Marte Lie
dc.date.accessioned2024-08-26T08:00:05Z
dc.date.available2024-08-26T08:00:05Z
dc.date.issued2024-03-02
dc.description.abstractBackground/Aims: To determine real-world medical and surgical treatment patterns in elderly-onset inflammatory bowel disease in a nationwide cohort, and to investigate associations between frailty and treatment choices.<p> <p>Methods: Norwegian health registries were used to identify adult-onset (born 1950–1989) and elderlyonset (born 1910–1949) patients with Crohn’s disease (CD) and ulcerative colitis (UC) diagnosed 2010– 2017 (n = 13,006). Patients were classified as no, low and intermediate/high frailty risk after the Hospital Frailty Risk Score. Outcomes included use of medical and surgical treatment. <p>Results: Within five years, elderly-onset patients received less biologics (13% [CD], 7% [UC]) and immunomodulators (24% [CD], 11% [UC]), and major surgery was more frequent (22% [CD], 9% [UC]) than in adult-onset. Respective log rank tests were significant (p < 0.01). Compared to no frailty risk groups, elderly-onset UC with intermediate/high frailty risk had lower probability of starting biologics (4% versus 9%), immunomodulators (7% versus 13%) and 5-aminosalisylic acids (66% versus 84%), and elderly-onset CD with intermediate/high frailty risk had higher probability of starting prednisolone (67% versus 49%). Respective log rank tests were significant (p < 0.05). <p>Conclusions: Elderly-onset patients received less biologics and immunomodulators and a larger proportion underwent major surgery. Frailty risk in elderly-onset patients was associated with increased use of prednisolone, and less use of 5-aminosalisylic acids, immunomodulators and biologics.en_US
dc.identifier.citationAnisdahl, Lirhus, Medhus, Moum, Melberg, Høivik. Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study. Digestive and Liver Disease. 2024en_US
dc.identifier.cristinIDFRIDAID 2260499
dc.identifier.doi10.1016/j.dld.2024.02.002
dc.identifier.issn1590-8658
dc.identifier.issn1878-3562
dc.identifier.urihttps://hdl.handle.net/10037/34417
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalDigestive and Liver Disease
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleFrailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry studyen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)